Metacrine: Jumps on positive liver treatment study

Metacrine

17/12/2020 14:07

** Shares of drug developer  MTCR.O  rise 10% to $10.8
premarket - set to open at two-month high
    ** Announces positive results from early-stage trial of its
liver disease treatment  urn:newsml:reuters.com:*:nGNX8vwhqj
    ** MTCR's MET642 is being developed for the treatment of
non-alcoholic steatohepatitis (NASH), a fatty liver condition
and inflammatory bowel disease
    ** Co plans to start phase-2 trial in H1 2021
    ** Currently there is no treatment available for NASH
patients

 (Reporting by Shivani Kumaresan in Bengaluru)
 ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780))